Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.1.1.69 (BMT)
 2,655 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We presented the results of Kanazawa experience and suggested integrative approach for treatment of acute leukemia in first remission. From 1977 to 1990, 23 patients with acute leukemia (AL) in first remission (ALL 13; ANL 10) were received marrow transplantation from HLA matched donor (allogeneic 22, syngeneic 1) after conditioning with CY + TBI (17), BU + CY (5) or AraC + BU + CY (1). Probability of 5 year survival in all AL patients is 52% (ALL 69%, ANL 30%). Relapse rate in all AL is 22% (ALL 38%, ANL 0%). The results of high risk ALL is superior to alternative approach of initial chemotherapy plus transplantation in subsequent remission. In addition, after 1987, there is no fatal cases within 100 days after transplantation. From current status of marrow transplantation and chemotherapy, together with our experience, we recommended initial allogeneic BMT for ANL and high risk adult ALL in first remission. BMT from unrelated matched donor or autologous marrow should be considered next. For high risk child ALL and low risk adult ALL, initial allogeneic BMT should be considered if related matched donor is available.
 ...
PMID:[Indication of bone marrow transplantation for acute leukemia in first remission]. 206 80

The activation of autologous cytotoxic cells by interleukin-2 (IL-2) may be a promising tool for elimination of minimal residual blast populations in patients with acute myelocytic leukemia (AML) to prolong disease-free survival. Here, we report the results of a phase II study using IL-2 for consolidation therapy in patients with second remission of de novo AML. All patients in 1st relapse of AML received a uniform induction therapy consisting of intermediate high-dose AraC (iHDAraC) 2 x 600 mg/m2 d1-4 and VP-16 100 mg/m2 d1-7. Patients achieving 2nd remission were treated with 4 cycles recombinant IL-2 (rIL-2) 9 x 10(6) IU/m2 administered on d1-5 and 8-12/cycle as 1h infusion every six weeks. In 37/66 (56%) evaluable patients, complete remission (CR) was achieved. So far, 21/37 patients (4 after additional autologous bone marrow transplantation (ABMT) received rIL-2 consolidation. Three patients are too early for evaluation, 4 received allogeneic BMT, 6 relapsed before IL-2 was scheduled and 4 refused treatment with rIL-2. The median disease-free survival (DFS) was 11 (4-49+) months. Up to now, in 5/21 (24%) patients the duration of 2nd remission exceeded that of 1st remission 7/21 (33%) are in ongoing 2nd remission (7+ to 49+ months). The side effects of rIL-2 were generally moderate and manageable. Only in two patients, previously treated with ABMT, severe side effects occurred; septicaemia and pneumonia in one patient and desquamative erythrodermia in the second one. In accordance with other studies rebound lymphocytosis with a marked increase of CD56(+)-cells and release of secondary cytokines such as TNF-alpha, IFN-gamma and IL-6 was observed. The schedule is feasible and the data suggest a possible benefit for DFS, which, however has to be confirmed by randomized trials.
 ...
PMID:Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia. 771 35

33 aplastic episodes in 24 patients undergoing bone marrow ablative therapy for the treatment of haematological malignancies were monitored with automated flowcytometric counts with particular emphasis to BLAST, MONO (monocytes) and LUC (large unstained cells) determined by Technicon H1, and MFR and HFR reticulocytes determined by Sysmex R1000. We found regular pattern of appearance of flowcytometric parameters, which were predictive for leucocyte recovery. A transient increase of BLAST to > 10% and MONO+LUC to > 0.08 x 10(9)/l were predictive for leukocyte recovery after aplastic episodes following ABMT, BMT and high dose AraC therapy, but not after conventional chemotherapy. The prognostic value of MFR+HFR reticulocytes increase over 5% was limited to ABMT and BMT. This report demonstrates the capabilities of automated flowcytometric analysis in early prediction of haematological recovery.
 ...
PMID:Flowcytometric pattern of leucocyte recovery after therapy induced aplasia. 784 34

We previously suggested that using a combined conditioning regimen including rhG-CSF with allogeneic BMT in refractory AML and CML in blast crisis might reduce the rate of relapse and improve disease-free survival, without any major side effects. In this study, we used the same protocol for 10 AML patients in complete remission (CR) and 6 CML patients in the chronic phase (CP). We compared disease-free survival as well as toxic side effects of the regimen with 6 AML patients in CR and 6 CML patients in CP treated with chemoradiotherapy without G-CSF. The conditioning regimen consisted of TBI and high-dose AraC. RhG-CSF was infused continuously at a dose of 5 microg/kg/day, starting 24 hr before the initial dose of total body irradiation (TBI) until the end of AraC therapy. In all 28 cases, there were no early stage deaths due to regimen-related toxicity (RRT). None of the 10 AML cases treated with the G-CSF combined regime relapsed. In 6 AML cases treated conventionally without G-CSF, one patient died of infection and another relapsed. There were no relapses in either CML group. In the combined G-CSF group, one patient died of interstitial pneumonitis 48 days after BMT, while the rest of the CML cases are still alive. There were no relapses with rhG-CSF and no serious adverse effects in terms of RRT, acute graft vs. host disease (GVHD), or leukocyte recovery.
 ...
PMID:Recombinant human granulocyte colony-stimulating factor (G-CSF) combined conditioning regimen for allogeneic bone marrow transplantation (BMT) in standard-risk myeloid leukemia. 954 74